bharat biotech

On 24th September, the journal Drug Safety retracted a paper it had published in May 2024 regarding the safety of Covaxin made by Bharat Biotech

Bharat Biotech said such analysis renders the findings insignificant. The company emphasised that “Rotavac is manufactured using human rotavirus strains, not of animal origin; hence, the rate of intussusception is similar in vaccinated and non-vaccinated subjects."

The vaccine was developed by the Jenner Institute at Oxford University and Serum Institute of India with support from the European and Developing Countries Clinical Trials Partnership (‘EDCTP’), the Wellcome Trust, and the European Investment Bank (‘EIB’).

Gavi, the vaccine alliance, to provide 18 million doses of malaria vaccine to African countries. Bharat Biotech and Serum Institute of India are going to be the manufacturers in the global effort.

An initial manufacturing capacity of several million doses per annum has been established, this can be scaled up to a billion doses as required. iNCOVACC is priced at INR 325/dose for large volume procurement by State Governments and Govt of India, as per an official release.

The firm said despite the relatively low demand for Covid vaccines, "Bharat Biotech continued product development in intranasal vaccines, to be well-prepared with platform technologies for future infectious diseases. Bharat Biotech has also initiated the development of variant-specific vaccines for COVID in an attempt to be future-ready".

Govt of India and Bharat Biotech deny claims that approval for Covaxin was rushed and procedures were skipped

Serum Institute of India and Bharat Biotech reduce the price of Covishield and Covaxin vaccines to ₹225 per dose

A court in Telangana has ordered The Wire to take down 14 articles it had published against Bharat Biotech

Booster dose of COVAXIN is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.